Hospital Sultanah Aminah Johor Bahru, Clinical School Johor Bahru, Monash University Malaysia, Johor Bahru, Malaysia.
Clínica Dermacross, Santiago, Chile.
J Eur Acad Dermatol Venereol. 2024 Feb;38(2):265-280. doi: 10.1111/jdv.19530. Epub 2023 Oct 13.
Generalized pustular psoriasis (GPP) is a rare, chronic, neutrophilic inflammatory skin disease characterized by episodes of widespread eruption of sterile, macroscopic pustules that can be accompanied by systemic inflammation and symptoms. A systematic literature review and narrative synthesis were conducted to determine the impact of GPP on patients' health-related quality of life (HRQoL) and patient-reported severity of symptoms and to compare its impact to patients with plaque psoriasis (plaque PsO). Searches were undertaken in Embase, MEDLINE and the Cochrane Library from 1 January 2002 to 15 September 2022. Screening was carried out by two reviewers independently. Outcome measures included generic (e.g. EQ-5D, SF-36) and dermatology-specific (e.g. DLQI) clinical outcome assessments, and other relevant patient-reported outcome measures (PROMs) (e.g. severity of pain measured by a numerical rating scale). Overall, 20 studies were found to be eligible for inclusion, of which seven also had data for plaque PsO. The DLQI was the most frequently reported outcome measure (16 out of 20 studies). When reported, mean DLQI (SD) scores varied from 5.7 (1.2) to 15.8 (9.6) across the studies, indicating a moderate to very large effect on HRQoL; the wide range of scores and large SDs were explained by the small population sizes (n ≤ 12 for all studies except two). Similar ranges and large SDs were also observed for other measures within individual studies. However, in general, people with GPP reported a greater impact of their skin condition on HRQoL, when compared to people with plaque PsO (i.e. higher DLQI scores) and higher severity for itch, pain and fatigue. This systematic review highlighted the need for studies with a larger population size, a better understanding of the impact of cutaneous and extracutaneous symptoms and comorbidities on HRQoL during and between GPP flares, and outcome measures specifically tailored to the unique symptoms and the natural course/history of GPP.
泛发性脓疱型银屑病(GPP)是一种罕见的、慢性的、中性粒细胞炎症性皮肤病,其特征为广泛发作无菌、大疱性脓疱,可伴有全身炎症和症状。进行了系统的文献回顾和叙述性综合分析,以确定 GPP 对患者健康相关生活质量(HRQoL)和患者报告的症状严重程度的影响,并将其与斑块型银屑病(斑块 PsO)患者进行比较。从 2002 年 1 月 1 日至 2022 年 9 月 15 日,在 Embase、MEDLINE 和 Cochrane 图书馆进行了检索。两名审查员独立进行了筛选。结果测量包括通用(如 EQ-5D、SF-36)和皮肤病学专用(如 DLQI)临床结果评估,以及其他相关患者报告的结果测量(如数字评定量表测量的疼痛严重程度)。总体而言,发现 20 项研究符合纳入标准,其中 7 项研究也有斑块 PsO 的数据。DLQI 是最常报告的结果测量(20 项研究中有 16 项)。当报告时,研究中的平均 DLQI(SD)评分从 5.7(1.2)到 15.8(9.6)不等,表明对 HRQoL 有中度至非常大的影响;由于研究人群规模较小(除了两项研究外,所有研究的 n 均≤12),评分范围很广,SD 很大。在个别研究中,其他测量也观察到类似的范围和大 SD。然而,一般来说,与斑块 PsO 患者相比(即 DLQI 评分更高),GPP 患者报告皮肤状况对 HRQoL 的影响更大,并且瘙痒、疼痛和疲劳的严重程度更高。这项系统综述强调了需要进行具有更大人群规模的研究,更好地了解皮肤和非皮肤症状和合并症对 GPP 发作期间和之间 HRQoL 的影响,以及专门针对 GPP 独特症状和自然病程/病史的结果测量。